Rituximab Reduces B Cells and T Cells in Cerebrospinal Fluid of Multiple Sclerosis Patients

Overview

Journal J Neuroimmunol

Specialty Neurology

Date 2006 Aug 15

PMID 16904756

Citations 187

Authors

Anne H Cross

Jennifer L Stark

Joanne Lauber

Michael J Ramsbottom

Jeri-Anne Lyons

Affiliations

Soon will be listed here.

Abstract

Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months post-treatment. ELISAs demonstrated modest reductions in serum antibodies to myelin oligodendrocyte glycoprotein and myelin basic protein in some subjects. Beta-interferon neutralizing antibodies were reduced in three subjects, but developed anew after treatment in three others, suggesting caution in considering rituximab as a means to eliminate NABs. In summary, rituximab depleted B cells from CSF at 24 weeks after initial treatment, and this B cell depletion was associated with a reduction in CSF T cells as well.

Citing Articles

Defining immune reset: achieving sustained remission in autoimmune diseases.

Junt T, Calzascia T, Traggiai E, da Costa A, Gergely P, Schett G Nat Rev Immunol. 2025; .

PMID: 40044810 DOI: 10.1038/s41577-025-01141-w.

Multiple Sclerosis: A Story of the Interaction Between Gut Microbiome and Components of the Immune System.

Mohsen E, Haffez H, Ahmed S, Hamed S, El-Mahdy T Mol Neurobiol. 2025; .

PMID: 39934561 DOI: 10.1007/s12035-025-04728-5.

Sequelae of B-Cell Depleting Therapy: An Immunologist's Perspective.

Kacar M, Al-Hakim A, Savic S BioDrugs. 2024; 39(1):103-130.

PMID: 39680306 DOI: 10.1007/s40259-024-00696-9.

Intrathecal IgG and IgM synthesis correlates with neurodegeneration markers and corresponds to meningeal B cell presence in MS.

Rodriguez-Mogeda C, van Gool M, van der Mast R, Nijland R, Keasberry Z, van de Bovekamp L Sci Rep. 2024; 14(1):25540.

PMID: 39462090 PMC: 11513002. DOI: 10.1038/s41598-024-76969-8.

Current Knowledge about CD3CD20 T Cells in Patients with Multiple Sclerosis.

Arneth B Int J Mol Sci. 2024; 25(16).

PMID: 39201672 PMC: 11354236. DOI: 10.3390/ijms25168987.

References

Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E . Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003; 171(3):1581-7. DOI: 10.4049/jimmunol.171.3.1581. View

DEIBLER G, Martenson R, KIES M . Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem. 1972; 2(2):139-65. DOI: 10.1080/00327487208061467. View

Olsson J, Link H . Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions. Arch Neurol. 1973; 28(6):392-9. DOI: 10.1001/archneur.1973.00490240052009. View

Tourtellotte W, POTVIN A, Fleming J, Murthy K, Levy J, Syndulko K . Multiple sclerosis: measurement and validation of central nervous system IgG synthesis rate. Neurology. 1980; 30(3):240-4. DOI: 10.1212/wnl.30.3.240. View

Kurtzke J . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52. DOI: 10.1212/wnl.33.11.1444. View

Walsh M, Tourtellotte W, Roman J, DREYER W . Immunoglobulin G, A, and M--clonal restriction in multiple sclerosis cerebrospinal fluid and serum--analysis by two-dimensional electrophoresis. Clin Immunol Immunopathol. 1985; 35(3):313-27. DOI: 10.1016/0090-1229(85)90092-3. View

Walsh M, Tourtellotte W . Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med. 1986; 163(1):41-53. PMC: 2188010. DOI: 10.1084/jem.163.1.41. View

Rodriguez M, Lennon V . Immunoglobulins promote remyelination in the central nervous system. Ann Neurol. 1990; 27(1):12-7. DOI: 10.1002/ana.410270104. View

Zhou S, Whitaker J . Specific modulation of T cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies. J Immunol. 1993; 150(4):1629-42. View

10.

Reff M, Carner K, Chambers K, Chinn P, Leonard J, Raab R . Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994; 83(2):435-45. View

11.

Zeman A, Kidd D, McLean B, Kelly M, Francis D, Miller D . A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996; 60(1):27-30. PMC: 486185. DOI: 10.1136/jnnp.60.1.27. View

12.

Grossberg S, KAWADE Y . The expression of potency of neutralizing antibodies for interferons and other cytokines. Biotherapy. 1997; 10(1):93-8. DOI: 10.1007/BF02678220. View

13.

Rudick R, Medendorp S, Namey M, Boyle S, Fischer J . Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains. Mult Scler. 1995; 1(3):150-5. DOI: 10.1177/135245859500100303. View

14.

Lyons J, San M, Happ M, Cross A . B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol. 1999; 29(11):3432-9. DOI: 10.1002/(SICI)1521-4141(199911)29:11<3432::AID-IMMU3432>3.0.CO;2-2. View

15.

Weinshenker B, OBrien P, Petterson T, Noseworthy J, Lucchinetti C, Dodick D . A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999; 46(6):878-86. DOI: 10.1002/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q. View

16.

Cross A, Trotter J, Lyons J . B cells and antibodies in CNS demyelinating disease. J Neuroimmunol. 2000; 112(1-2):1-14. DOI: 10.1016/s0165-5728(00)00409-4. View

17.

Avasarala J, Cross A, Trotter J . Oligoclonal band number as a marker for prognosis in multiple sclerosis. Arch Neurol. 2001; 58(12):2044-5. DOI: 10.1001/archneur.58.12.2044. View

18.

Izquierdo G, Angulo S, Garcia-Moreno J, Gamero M, Navarro G, Gata J . Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients. Acta Neurol Scand. 2002; 105(3):158-63. DOI: 10.1034/j.1600-0404.2002.1o009.x. View

19.

Villar L, Masjuan J, Gonzalez-Porque P, Plaza J, Sadaba M, Roldan E . Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology. 2002; 58(5):824-6. DOI: 10.1212/wnl.58.5.824. View

20.

Bernasconi N, Traggiai E, Lanzavecchia A . Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2002; 298(5601):2199-202. DOI: 10.1126/science.1076071. View